Fig. 2From: Oleogel-S10 Phase 3 study “EASE” for epidermolysis bullosa: study design and rationaleStudy visit schedule. BSAP body surface area percentage, CCC confirmation of complete closure of the EB target wound, D day, EBDASI Epidermolysis Bullosa Disease Activity and Scarring Index, EDBP end of double-blind phase, FLACC Face, Legs, Activity, Cry, Consolability scale, TSQM Treatment Satisfaction Questionnaire for Medication; V visit, W-QoL Wound-Quality of Life QuestionnaireBack to article page